Dear Editor: We read the recent article, “Recurrence of Localized Pemphigus Foliaceus Induced by Knee Replacement,” with great interest.1 The authors attribute the presentation of unilateral pemphigus foliaceus (PF) in a previously uninvolved site to an immunocompromised district (ICD), where edema and nerve injury paved the way for a buildup of immunoglobulins and immune cells. […]

Dear Editor: Onychocryptosis, or ingrown nail (IN) is a common problem in dermatology clinical practice. Its prevalence is estimated to be from 2.5 to 5 percent, with a predominance in males.1 The incidence has a bimodal age-related peak: it appears to be higher among teenagers and young adults, but also shows a strong predominance in […]

Dear Editor: No other single medical product has revolutionized and quite literally defined the aesthetic medicine field like botulinum toxin injections.1–5 Every year, a growing number of patients experience the cosmetic benefits of neurotoxin products as indications for use expand and new formulations are introduced into the marketplace.6 The vast clinical experience gained over the […]

Dear Editor: Hemangioma is a common term to describe a benign proliferative lesion of vascular tissue origin that can be present either at birth or appear during childhood.1 Hemangiomas are developmental vascular abnormalities characterized by a proliferative growth phase and a very slow, inevitable regression (involutive phase). They are histologically classified into capillary and cavernous […]

Dear Editor: Dermatology has always been a family, even a cult, as I have said, and we all miss our family members horribly as meetings continue to fall like dominoes. Anyone who doesn’t get it either isn’t part of it or probably wants to destroy it. And like it or not (another Genesis song), it […]

Dear Editor: We are writing to express our deep concerns regarding the accuracy and/or scientific integrity of a paper published in the August 2019 issue of The Journal of Clinical and Aesthetic Dermatology titled “Safe and Efficacious Use of Secretome From Fibroblasts and Adipose-derived (but not Bone Marrow–derived) Mesenchymal Stem Cells for Skin Therapeutics.” The […]

Dear Editor: Dulaglutide is a glucagon-like peptide (GLP-1) receptor agonist, which stimulates insulin release via activation of GLP-1 receptors on pancreatic beta cells. Here, we report the first case of morbilliform drug eruption to dulaglutide. Case presentation. An 84-year-old male patient with a medical history of Type 2 diabetes mellitus, hyperlipidemia, hypertension, and back pain […]